Pioneering Medical Research Company Specializing in Remote Clinical Trials Expands Therapeutic Focuses Through Strategic Executive Appointments in the areas of Endocrinology, Neurology, Psychiatry, and Psychology
PLAYA VISTA, Calif. (November 6, 2017) – Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the recent executive team appointments of Gerald Todd Adamson, Psy.D. – Associate Medical Director, Psychiatry and Behavioral Sciences; Henry Anhalt, D.O. – Vice President, Medical Affairs; Benjamin Furst, M.D. – Medical Director, Psychiatry and Behavioral Sciences; David Kudrow, M.D. – Medical Director, Neurology; and Ann Neale, RN, BS – Senior Vice President Clinical Operations. The Medical Affairs team has also expanded to six full-time dermatologists, attesting to the company’s continued strategic growth in Dermatology.
The level of expertise gained by this expanded management team will help further guide the expansion of cutting-edge treatments for a multitude of medical-related issues using the company’s decentralized Metasite™ model enabled through its proprietary technology platform, the Network Orientated Research Assistant (NORA®), a cloud-based patient-centric mobile research platform that connects patients safely and securely to experts and research staff 24/7.
“Growing a strong internal team of experienced physician-scientists and clinical operations leaders has been one of our top priorities this year and we’re very proud of the incredible talent we’ve recruited,” said Belinda Tan, MD, PhD, co-founder and chief medical officer of Science 37. “Our team is a unique asset that allows us to maintain our mission to accelerate biomedical research by putting patients first, and ensure consistent high-quality standards in our trial execution.”
As Vice President of Medical Affairs leading trials focused on Diabetes and metabolism, Dr. Anhalt will collaborate directly with sponsors to develop study concepts, design patient-centric protocols, and explore relevant outcomes and endpoints. Lending his over 20 years of subject matter expertise, Dr. Anhalt will also conduct clinical trial feasibility analysis and serve as principal investigator for clinical trials conducted by Science37. Dr. Anhalt sits on the board of Insulin for Life USA (IFLUSA), he is also Chair of The Hormone Health Network of the Endocrine Society. He completed his medical school studies at the New York College of Osteopathic Medicine and his Fellowship in Pediatric Endocrinology at Stanford University.
Dr. Adamson is a licensed clinical psychologist with specialized training in Trauma-focused CBT, Cognitive Processing Therapy, and Prolonged Exposure Therapy. With this expertise he will join the Science 37 team as Associate Medical Director of Psychiatry and Behavioral Sciences, and will help build and assess neuroscience-focused research studies for the company. Recently, Dr. Adamson completed a Department of Defense funded study that treated severe mental illness and PTSD in military veterans through the aid and application of Virtual Reality technology. Dr. Adamson completed his undergraduate studies in Psychology at the University of Georgia, and went on to receive his Master of Arts and Doctorate in Psychology from the California School of Professional Psychology at Alliant International University.
Dr. Furst joins the Science 37 team as Medical Director of Psychiatry and Behavioral Sciences. In this role, he will help set up internal mechanisms and assessment protocols for developing trials focused on mental health. He has been a crucial part of Science 37’s team of expert clinicians and advisor for over a year. Dr. Furst received his B.A. in American Studies and Biology from the University of Southern California and conducted his residency training in Psychiatry at the UCLA Semel Institute.
Dr. Kudrow joins the team as Medical Director of Neurology. In this role, Dr. Kudrow will lend his over 22 years of expertise as a neurologist to the roster of clinical trials being conducted by Science 37 focused on treating neurological disorders. Dr. Kudrow is a board-certified neurologist with specialty focus in headache medicine and has been a principal investigator and consultant at Science 37 for the last year and a half. Dr. Kudrow received his B.A. from the University of Southern California, his M.D. at the Geffen School of Medicine at UCLA, and conducted his fellowship at Harbor-UCLA Medical Center.
Ann Neale is the new Senior Vice President of Clinical Operations and Patient Affairs. As a key member of the executive management team, her primary role will be optimizing Clinical Operations, Patient Affairs, and Clinical Solutions, working collaboratively with external partners and stakeholders. Neale brings over 27 years of sponsor pharmaceutical and biotech experience with her to Science 37 and has directed clinical operations and development programs for over 50 U.S. and Global Phase 1-4 clinical trials with individual studies of more than 100 sites and 600 patients. Neale received a B.S. in Nursing from the University of Minnesota.
Science 37’s core offering is focused on making clinical trials better for patients using their proprietary Metasite™ and technology platform, the Network Oriented Research Assistant (NORA®) that patients can access from the comfort of their homes. The Metasite™ decentralizes trials, enabling patients to participate regardless of their geographical location using study mobile devices and telemedicine services, and includes Virtual Trial Specialists, mobile nursing companies when needed, and study monitors to execute end-to-end clinical trial services for sponsors.
About Science 37
Science 37 is a Los Angeles-based technology-enabled clinical research company. They created a new clinical trial operating model – the Metasite™ – that unlocks access so researchers can find the right patients, and patients can find the right trials. Their Network Orientated Research Assistant, NORA®, is the cloud-based patient-centric mobile research platform that connects everyone – safely and securely. Science 37 offers end-to-end clinical trial services without geographic limitations, making clinical research faster to accelerate biomedical discovery. Ultimately, Science 37 enables better, faster people-powered science and brings clinical trials to scale. Learn more at http://www.science37.com, and follow Science 37 on Twitter @Science_37.